We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Otorhinolaryngology

Otorhinolaryngology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial
newsclinical trialoropharyngeal cancer

Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial

By MedXY|Jan 14, 2026

A landmark Phase 3 trial establishes Intensity-Modulated Proton Therapy (IMPT) as a new standard for oropharyngeal cancer, demonstrating non-inferior progression-free survival, significantly improved overall survival, and a marked reduction

Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer
newsctDNAhead and neck cancer

Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer

By MedXY|Jan 13, 2026

Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting l

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes
newsHNSCCimmunotherapy

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes

By MedXY|Jan 13, 2026

A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcino

Beyond PD-1: The Rise of Anti-LAG-3 Antibody LBL-007 in Fighting Nasopharyngeal Carcinoma
newsimmunotherapynasopharyngeal carcinoma

Beyond PD-1: The Rise of Anti-LAG-3 Antibody LBL-007 in Fighting Nasopharyngeal Carcinoma

By MedXY|Jan 11, 2026

Recent clinical trials reveal that LBL-007, a novel anti-LAG-3 antibody, significantly enhances treatment outcomes for advanced nasopharyngeal carcinoma when combined with PD-1 inhibitors, marking a potential shift in the standard of care f

FDG-PET-Guided Dose De-escalation: A New Standard for HPV-Positive Oropharyngeal Cancer?
newsFDG-PEToncology

FDG-PET-Guided Dose De-escalation: A New Standard for HPV-Positive Oropharyngeal Cancer?

By MedXY|Jan 11, 2026

A multi-center phase II trial demonstrates that mid-treatment FDG-PET imaging can safely identify patients with HPV+ oropharyngeal cancer for radiation dose reduction, resulting in non-inferior tumor control and significantly improved quali

Neoadjuvant Nivolumab plus Chemotherapy Redefines Pathologic Response in Locally Advanced Resectable Head and Neck Cancer
newshead and neck cancerneoadjuvant therapy

Neoadjuvant Nivolumab plus Chemotherapy Redefines Pathologic Response in Locally Advanced Resectable Head and Neck Cancer

By MedXY|Jan 11, 2026

This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally

INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC
newsHNSCCimmunotherapy

INDUCE-3 Trial Fails to Support Feladilimab-Pembrolizumab Combination in First-Line HNSCC

By MedXY|Jan 11, 2026

The Phase II/III INDUCE-3 trial was terminated early after the ICOS agonist feladilimab plus pembrolizumab failed to show superiority over pembrolizumab monotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma

Precision Prognosis: Navigating Decision-Making in Head and Neck Cancer Through Individualized Counseling
Clinical UpdatesHNSCCShared Decision-Making

Precision Prognosis: Navigating Decision-Making in Head and Neck Cancer Through Individualized Counseling

By MedXY|Jan 6, 2026

This review analyzes the impact of individualized prognostic counseling on decisional conflict and regret in patients with head and neck squamous cell carcinoma, highlighting the efficacy of online prognostic tools in fostering shared decis

Deep Transfer Learning and Preimplant MRI: A Paradigm Shift in Predicting Pediatric Cochlear Implant Outcomes
AICochlear ImplantsNeuroimaging

Deep Transfer Learning and Preimplant MRI: A Paradigm Shift in Predicting Pediatric Cochlear Implant Outcomes

By MedXY|Dec 29, 2025

A multicenter study demonstrates that deep transfer learning (DTL) algorithms using preimplant MRI can predict spoken language development in children with cochlear implants with over 92% accuracy, significantly outperforming traditional ma

Active Surveillance Superior to Surgery for Quality of Life in Low-Risk Thyroid Cancer: Insights from a Global Meta-Analysis
newsactive surveillancepatient-reported outcomes

Active Surveillance Superior to Surgery for Quality of Life in Low-Risk Thyroid Cancer: Insights from a Global Meta-Analysis

By MedXY|Dec 28, 2025

A comprehensive meta-analysis demonstrates that patients with papillary thyroid microcarcinoma managed via active surveillance experience significantly better health-related quality of life and fewer treatment-related symptoms than those un

Thyroid Lobectomy and Neck Dissection Offer Comparable Survival to Total Thyroidectomy in Selected N1b Papillary Thyroid Carcinoma
newsPapillary Thyroid Carcinoma

Thyroid Lobectomy and Neck Dissection Offer Comparable Survival to Total Thyroidectomy in Selected N1b Papillary Thyroid Carcinoma

By MedXY|Dec 24, 2025

A landmark propensity-matched study from Memorial Sloan Kettering Cancer Center demonstrates that thyroid lobectomy with neck dissection provides similar survival and recurrence outcomes to total thyroidectomy plus radioactive iodine for sp

Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC
newsHNSCCimmunotherapy

Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC

By MedXY|Dec 23, 2025

A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate

Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer
newsoncologyoral cavity cancer

Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer

By MedXY|Dec 21, 2025

A prospective cohort study demonstrates that a structured shared decision-making (SOP) model significantly increases the utilization of multidisciplinary palliative care services for patients with stage IV oral cavity cancer, bridging the g

Integrated Multidisciplinary Care Slashes Radiotherapy Interruptions in Head and Neck Cancer: Results from the SHINE-MDT Randomized Trial
newshead and neck cancerRadiotherapy

Integrated Multidisciplinary Care Slashes Radiotherapy Interruptions in Head and Neck Cancer: Results from the SHINE-MDT Randomized Trial

By MedXY|Dec 21, 2025

A randomized clinical trial demonstrates that the SHINE-MDT framework significantly reduces radiotherapy interruptions and improves nutritional, psychological, and quality-of-life outcomes for patients with head and neck cancer, offering a

Biofeedback vs Respiratory Retraining: No Significant Difference in Inducible Laryngeal Obstruction Relief
newsbiofeedback

Biofeedback vs Respiratory Retraining: No Significant Difference in Inducible Laryngeal Obstruction Relief

By MedXY|Dec 17, 2025

A pilot trial finds biofeedback and respiratory retraining equally effective for inducible laryngeal obstruction, offering clinicians flexible, patient-tailored options.

Your Nose Knows: How Smell Loss Signals More Than a Cold — Links to 139 Diseases and What to Do About It
Neurologyneurologyolfaction

Your Nose Knows: How Smell Loss Signals More Than a Cold — Links to 139 Diseases and What to Do About It

By MedXY|Dec 13, 2025

A large prospective study links smell disturbances to at least 139 conditions. Olfactory loss can be an early sign of neurological, ENT, metabolic, or systemic disease — and a practical, underused screening tool clinicians can adopt.

Radiotherapy Interruptions in Head and Neck Cancer Raise Risk of Locoregional Failure and Death — Impact Depends on p16 Status and Stage
newshead and neck cancerp16

Radiotherapy Interruptions in Head and Neck Cancer Raise Risk of Locoregional Failure and Death — Impact Depends on p16 Status and Stage

By MedXY|Dec 8, 2025

Secondary analysis of three RTOG/NRG trials shows radiotherapy interruptions are associated with higher locoregional failure and worse overall survival in head and neck cancer, with larger absolute harms in p16‑negative and high‑stage disea

Clinical Findings and Molecular Genetics of USH1C-Associated Usher Syndrome: A Retrospective Case Series
newscase reportdiagnosis

Clinical Findings and Molecular Genetics of USH1C-Associated Usher Syndrome: A Retrospective Case Series

By MedXY|Nov 27, 2025

This case series reviews clinical features, genetic variants, visual outcomes, and psychosocial impact in 28 patients with USH1C-associated Usher syndrome, highlighting slow retinal degeneration and significant social burden.

Higher Osteoradionecrosis Risk After Proton Therapy than IMRT in Oropharyngeal Cancer — What Clinicians Should Know
newsIMRTproton-therapy

Higher Osteoradionecrosis Risk After Proton Therapy than IMRT in Oropharyngeal Cancer — What Clinicians Should Know

By MedXY|Nov 27, 2025

In a large single‑institution cohort of oropharyngeal squamous cell carcinoma, proton therapy was associated with a higher 3‑year rate of osteoradionecrosis than IMRT (6.4% vs 2.7%), though severe ORN remained uncommon.

Engasertib Shows Promise for Reducing Epistaxis in HHT but Benefits Are Modest — Safety Profile Acceptable in Short Term
newsengasertibepistaxis

Engasertib Shows Promise for Reducing Epistaxis in HHT but Benefits Are Modest — Safety Profile Acceptable in Short Term

By MedXY|Nov 27, 2025

A randomized, double-blind placebo-controlled proof-of-concept trial of engasertib (AKT inhibitor) in hereditary hemorrhagic telangiectasia showed modest reductions in epistaxis frequency and duration versus placebo and a tolerable safety p

Prev
9 / 13
1…7891011…13
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles